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Patients in the intensive care unit (ICU) often require the concomi-
tant administration of several drugs. However, ICU patients display 
marked differences in pharmacokinetics compared with healthy 
persons.1,2 For example, changes in volume of distribution can re-
sult in inadequate plasma drug concentrations, whereas decreased 
clearance may increase the risk of toxicity.2,3 Reduced protein bind-
ing resulting from a lower plasma albumin concentration may in-
crease drug clearance thereby lowering the total drug concentration 
without effect on the unbound drug concentration with the risk of 
unnecessary increases of drug doses. Therapeutic drug monitoring 
(TDM) is therefore essential in these patients to optimize antimicro-
bial treatment.4 To adequately assess the patients’ pharmacokinet-
ics multiple blood samples are required, which can be distressing to 
the patient. Moreover, the unbound drug concentration exerts the 
therapeutic effect and is the best predictor of the effectiveness and 
is highly variable in these patients,5 yet this requires a laborious and 
expensive separation step. A method for directly measuring the un-
bound concentration is preferred.6
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A central venous catheter with a built- in microdialysis membrane is available for 
continuous lactate and glucose monitoring in the intensive care unit (ICU). As this 
catheter might also be suitable for repeated measurements of unbound drug lev-
els, we studied in vitro the feasibility of monitoring unbound antibiotic concentra-
tions. The catheter was placed in various media at 37°C spiked with gentamicin or 
vancomycin. Dialysate fractions were repeatedly collected over 3 hours with a NaCl 
0.9% perfusate flow of 5 μL/min. Total and unbound drug concentrations in medium 
and perfusate were measured by immunoassay. After 60 minutes stable recovery for 
both drugs was observed, with mean ±SD relative recoveries of vancomycin and gen-
tamicin in human serum of 64% ±0.4% and 73% ±3%. The recoveries of the unbound 
concentrations were 91% ±3% and 91% ±4%. This intravenous microdialysis system 
may be a very useful platform for therapeutic drug monitoring in the ICU.
K E Y W O R D S
gentamicin, intensive care unit, intravenous microdialysis, therapeutic drug monitoring, 
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The commercially available intravenous microdialysis EIRUS® 
catheter has been designed for use in ICU patients to continuously 
monitor lactate and glucose at the bedside.7 This catheter is a stan-
dard triple- lumen intravenous catheter, which integrates a novel 
microdialysis function (Figure 1) which strongly reduces the need 
for lactate and glucose blood sampling for up to 30 days.7 Central 
venous catheters (CVC) are used in the majority of ICU patients.
We hypothesized that an intravenous microdialysis catheter may 
therefore serve as an ideal platform for repeated measurements of 
the circulating unbound concentrations of many drugs. The aim of 
this study was to investigate the usability of intravenous microdi-
alysis for TDM of vancomycin and gentamicin in an in vitro setting.
2  | MATERIAL S AND METHODS
2.1 | Materials
Vancomycin 1000 mg (Xellia Pharmaceuticals ApS, Copenhagen, 
Denmark) and gentamicin 10 mg/mL (Centrafarm B.V., Etten- Leur, 
the Netherlands) were used as model drugs. Human serum was 
purchased from Millipore (Darmstadt, Germany), Human plasma 
(Omniplasma) and albumin (Albuman) were obtained from Sanquin, 
Amsterdam, the Netherlands. NaCl 0.9% was obtained from Baxter 
(Viaflo, Utrecht, the Netherlands). Ammonium acetate, disodium 
phosphate and potassium phosphate were used in the buffers and 
were obtained from Merck (Merck Millipore Ltd., Cork, Ireland). All 
other chemicals were of analytical grade and used as obtained.
2.2 | Catheter
All experiments were carried out with EIRUS® (Maquet Critical Care, 
Solna, Sweden) catheters 14G, triple lumen, 5000 Da cutoff. The mi-
crodialysis function was not affected when the catheter was used 
for infusions and drug administration, since the dialysis membrane 
is physically separated from and located “upstream” relative to the 
catheter tip (Figure 1). The microdialysis catheter uses a 0.9% NaCl 
carrier fluid as perfusate with a continuous flow of 5 μL/min.8
Figure 1 shows a schematic drawing of the catheter. The outer 
diameter of the CVC is approximately 2 mm. The microdialysis mem-
brane is close to 3 mm in diameter and the effective length of the 
microdialysis chamber is approximately 35 mm, constituting a mem-
brane contact surface of approximately 330 mm2.
Prior to use, the system requires equilibration for 10 minutes.8,9 
With a flow of 5 μL/min it takes 5 minutes between diffusion in the 
microdialysis chamber and collecting fractions of the dialysate at the 
microdialysis outlet (Figure 1C) resulting in a lag time of 5 minutes.10
CVC's were re- used, cleaned between experiments with blank 
medium and perfusate. Prior to starting each experiment, a dialysate 
sample was measured to determine that the CVC's were free of drugs.
2.3 | In vitro set- up
Drugs were added to a test- tube in a therapeutic relevant range, that 
is, vancomycin 15 to 22 mg/L and gentamicin 8 to 22 mg/L, con-
taining a medium surrounding the catheter before the start of the 
microdialysis. The medium was constantly stirred to simulate blood 
flow	and	optimize	microdialysis	and	kept	at	37⁰C	using	a	water	bath.	
T = 0 was defined as the time the catheter was placed in the test 
medium. Samples were simultaneously collected from the medium 
and dialysate, to calculate the relative recovery (RR).
The perfusate inlet of the CVC was connected to an adjust-
able low- flow pump (Alaris® GH Syringe Pump, CareFusion, Rolle, 
Switzerland) at a flow rate that was used in previous studies 0.3 mL/h 
(5 μL/min).7,9-13
2.4 | Media
The in vitro testing started using a 0.9% NaCl solution as medium. 
In subsequent measurements, the medium complexity was gradually 
increased from saline to human serum:
F IGURE  1 The EIRUS CVC: (A) 
perfusate inlet, (B) semipermeable 
membrane with a cutoff below 5000 Da, 
(C) microdialysate outlet, (D) three 
lumens for the administration of drugs, 
(E) an enlargement of the semipermeable 
membrane. Whereas large molecules 
(depicted as red dots) cannot pass the 
membrane, small molecules (<5000 Da, 
depicted as green dots) can pass it, thus 
arriving in the perfusate and creating a 
dialysate. The perfusion fluid flows from 
the perfusate inlet (A), via the distal end of 
the microdialysis chamber to the proximal 
site, and the dialysate leaves the catheter 
via the microdialysate outlet (C)
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Medium 1: NaCL 0.9% solution.
Me dium 2: 0.2 M ammonium acetate buffer (set at pH 7.4 using 
ammonia).
Medium 3: 0.2 mmol/L phosphate buffer (pH 7.4).
Me dium 4: 0.2 mmol/L phosphate buffer with albumin 40 g/L 
(pH 7.1).
 Medium 5: 0.2 mmol/L phosphate buffer with albumin 40 g/L in 
NaCl 0.9% (pH 6.9).




2.5 | Analysis of drug concentrations
Dialysate fractions of 50 μL (10 min) or 100 μL (20 min) and 100 μL 
samples of medium were simultaneously collected. The unbound frac-
tions from the media were obtained using ultrafiltration (Centrifree® 
Ultrafiltration Devices, Merck Millipore Ltd., Cork, Ireland) to separate 
the bound concentration and the unbound concentration. Gentamicin 
and vancomycin total concentrations and unbound concentrations 
were measured using an immunoassay (Abbott® Architect c8000 
analyzer, Abbott Laboratories, North Chicago, IL, USA), with a coef-
ficient of variation < 5% and a Lower Limit of Quantification (LLOQ) 
of 0.5 mg/L and 2.00 mg/L, respectively. The intraday and interday 
precision and accuracy of this assay was determined by a recovery 
study on spiked samples. The accuracy of this assay is continuously 
monitored by participation in external quality control programs.14,15
2.6 | Determination of Relative Recovery (RRT and 
RRU)
The recovery was calculated using drug concentrations in the di-
alysate fractions and in the external medium. The recovery of the 
total concentration (RRT) is the ratio between the concentrations 
of the substance in the dialysate to the total concentration in the 
external media using the formula:
The relative recovery of the unbound concentration (RRU) is the 
ratio between the concentrations of the substance in the dialysate to 
the unbound concentration in the external media using the equation:
The mean RRT and RRU were calculated after 60 minutes.
2.7 | Statistical analysis
All experiments were performed in triplicate. Mean and standard 
deviation were calculated. A t- test was calculated using Excel (MS 
Office 2010).
3  | RESULTS
Table 1 shows an overview of the results of the vancomycin meas-
urements. As can be seen, the complexity of the medium affects the 
RRT. When albumin was added to the medium, RRT decreased. The 
mean RRT of vancomycin in human serum was 64% ±0.4% and 91% 
±3% for the RRU.
The results of the gentamicin measurements are also summa-
rized in Table 1. The RRT of gentamicin in a phosphate buffer was 
close to 100%. When albumin was added to the phosphate buffer, 
RRT decreased to 65%. A RRU of 104% was observed. The mean 
RRT for gentamicin in human serum was 73% ±3.1% and 91% ±3.7% 
for the RRU.
Figure 2 shows the RRT of the total drug concentration of gen-
tamicin and vancomycin in human serum, expressed in the duration 
of microdialysis. As can be seen in the Figure 2, after one hour equi-
librium was achieved. The mean RRT of gentamicin in human plasma 
during equilibrium was 78.9%.
The stability of drug recovery was tested using a t-test. For both 
gentamicin and vancomycin a constant recovery was observed after 
60 minutes: the t- test showed significant difference prior to 60 min-
utes, and no significant difference after 60 minutes.
4  | DISCUSSION
In this study, we have evaluated the in vitro suitability of an intrave-
nous microdialysis CVC for TDM of vancomycin and gentamicin. The 
EIRUS CVC is an attractive device for continuous lactate and glucose 
measurements in critically ill patients,7-13 due to a high surface area 
and a high perfusion flow rate compared to microdialysis in tissue or 
peripheral veins. In addition, combination of the microdialysis mem-
brane on a CVC avoids the local trauma response and inflammatory 
response observed with tissue microdialysis.16 Moreover, tissue drug 
concentrations may not be the same as circulating concentrations or 
concentrations in the relevant tissues. Therefore, intravenous micro-
dialysis is preferable.
The molecular weight membrane cut- off (5000 Da for EIRUS) 
allows lactate (89 Da) and glucose (180 Da) to freely cross the mem-
brane. Usually, molecules with a molecular weight of one- fourth of 
the molecular weight cut- off of the membrane can reach an accept-
able recovery level.16 Gentamicin has a molecular weight of 478 Da 
and vancomycin has a molecular weight of 1486 Da. These molecular 
weights are approximately 2 fold and 8 fold higher than glucose.17 
Moreover, vancomycin was selected as a “worst case” scenario drug. 
If vancomycin with its relatively large molecular weight and positive 
charge at physiological pH would pass the membrane we hypothe-
size that many smaller and less charged drugs of interest will pass 
the membrane.
Recovery is influenced by the membrane area: the larger the 
surface area, the higher the recovery since equilibrium is reached 
faster.16 The intravenous microdialysis catheter had a membrane 
surface area of approximately 330 mm2: two orders of magnitude 
RRT (%)=
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larger than most subcutaneous microdialysis probes, resulting in a 
faster equilibrium and making it ideal for TDM. Another advantage is 
that samples are free of enzymes after dialysis, which results in more 
stable samples that require less processing.16
The composition of the dialysate and the constitution of the 
sample matrix influences the recovery.16 When increasing the com-
plexity of the sample matrix the RRT decreased due to protein bind-
ing of the drug. The perfusion fluid was not varied and the standard 
EIRUS perfusate was used: NaCl 0.9%.9 The time required to achieve 
a stable RRT or RRU was approximately 1 hour (P < 0.05), which is 
similar to the lactate and glucose measurements.9 This lag time is 
likely due to the time needed to flush the system to stabilize non 
selective adhesion in the microdialysis membrane and catheter af-
fecting the recovery.
When increasing the osmolarity from 308 to 616 mOsm/L, the recov-
ery of vancomycin increased from 69% to 74% likely caused by the con-
centration gradient and increased diffusion rate. Differences in osmotic 
pressure result in a convective flow and is induced by the movement 
F IGURE  2 Relative recovery of the 
total concentration (RRT) of gentamicin 
and vancomycin in human plasma
TABLE  1 Experimental conditions and results for in vitro microdialysis
External medium 
Vancomycin





dialysate (mg/L) RRT (%) RRU (%)
Medium 1 17.1 (17.0- 17.3) AI*** 13.0 (12.1- 13.5) 76.3 ± 4.5 AI***
Medium 2 19.0 (18.6- 19.6) AI*** 14.6 (13.4- 15.3) 78.5 ± 1.8 AI***
Medium 3 17.5 (16.8- 18.1) AI*** 16.2 (16.1- 16.4) 92.9 ± 3.3 AI***
Medium 4 17.6 (17.5- 17.6) 6.7 (6.6- 7.4) 9.3 (8.8- 9.8) 53.1 ± 2.8 137.2 ± 7.8
Medium 5 17.3 (17.3- 17.4) 10.3 (10.3- 10.4) 12.0 (11.7- 12.3) 68.9 ± 1.6 116.7 ± 2.9
Medium 6* 18.9 (18.9- 18.9) 13.3 (13.3- 13.3) 14.0 (13.8- 14.2) 74.5 ± 1.7 105.4 ± 1.6
Human plasma 19.2 (15.5- 21.9) 13.2 (10.0- 14.9) 11.6 (10.0- 12.7) 59.9 ± 4.9 89.2 ± 4.9
Human serum 19.0 (18.4- 19.4) 13.2 (13.2- 13.2) 12.1 (11.6- 12.4) 63.6 ± 0.4 90.7 ± 2.9
Gentamicin
Medium 3 21.8 (21.6- 21.9) AI*** 21.5 (21.1- 21.8) 98.7 ± 0.5 AI***
Medium 5 11.6 (11.5- 11.6) 7.3 (7.2- 7.4) 7.5 (7.4- 7.8) 65.2 ± 2.2 103.6 ± 1.1
Human plasma** 10.7 (8.9- 12.6) 8.9 (7.7- 10.9) 8.4 (7.1- 9.6) 78.9 ± 2.7 91.7 ± 2.9
Human serum* 9.8 (7.8- 11.8) 7.7 (6.6- 8.9) 7.1 (5.8- 8.3) 72.6 ± 3.1 90.7 ± 3.7
Medium and dialysate concentrations, relative recovery of the total concentration (RRT) and recovery of the unbound concentration (RRU) for van-
comycin and gentamicin using different external media. Mean ±SD. The human serum experiment of gentamicin and medium 6 of vancomycin were 
repeated twice (*) and the human serum experiment four times (**).
***AI: assumed identical to the total concentration as all the antibiotic was assumed unbound in these media that contained no protein. 
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of water molecules across the semi- permeable membrane which in turn 
affects the rate of passage of small water- soluble molecules.18
The results of this study show a steady recovery of both drugs in the 
dialysate from buffer, human serum and human plasma. Intravenous 
microdialysis may therefore provide reliable information to improve 
TDM in the critically ill: measurements can be performed continu-
ously, allowing for immediate action once concentration deviates from 
the desired value. In addition, only the unbound drug can pass the 
membrane: the unbound drug is the active drug concentration which 
can fluctuate in critically ill due to variation of the protein concentra-
tion.6 Reported unbound fractions for vancomycin vary between 45% 
and 95%.19,20 In addition, due to large fluctuations in the unbound 
concentration of vancomycin in critically ill patients, measuring the 
unbound concentration might further improve TDM of vancomycin.5 
The use of a combined CVC with an integrated microdialysis system, 
such as the EIRUS, is a potential approach for TDM of unbound drug 
concentrations in the ICU. Further research could focus on trough and 
peak sampling and prolonged measurements. Also studies on drugs 
with higher protein binding where measurement of the unbound con-
centration is particularly relevant (eg, ceftriaxone) are warranted to 
further investigate the opportunities and limitations of intravascular 
microdialysis. Although we restricted ourselves to the fluid and flow 
conditions designed for glucose and lactate measurements, other per-
fusates or flows might allow even better drug recovery.
In conclusion, this study shows that intravenous microdialysis 
is an accurate and useful platform for unbound drug monitoring of 
gentamicin and vancomycin without serial blood sampling and could 
be very useful in the ICU. This method may improve patient care as 
well comfort and deserves further clinical evaluation.
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